Actively Recruiting
A Pilot Study in Severe Patients With Takayasu Arteritis.
Led by Shanghai Zhongshan Hospital · Updated on 2021-08-10
40
Participants Needed
1
Research Sites
200 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. We classify TAK patients into 3 levels, including mild, moderate, and severe. And the biological agents tocilizumab and adalimumab are randomly prescribed in severe patients, to find out the relatively better treatment strategy, facilitating better intervention strategy in severe TAK patients.
CONDITIONS
Official Title
A Pilot Study in Severe Patients With Takayasu Arteritis.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 14 years or older
- Active disease with Kerr score of 2 or more
- Severe disease defined by at least one of the following: blood pressure over 180/110 mmHg; involvement of three or more artery branches with stenosis over 70%; significant organ insufficiency including NYHA class III-IV heart failure or eGFR 15-60 ml/min
You will not qualify if you...
- Severe organ insufficiency
- Active infections including tuberculosis and hepatitis
- Other autoimmune diseases such as systemic lupus erythematosus, Behcet disease, or IgG4-related disease
- Malignant tumors
- History of severe drug allergy
- Two successive relapses despite intervention adjustments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Rheumatology in Zhongshan hospital, Fudan University
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
R
Rongyi Chen, PhD
CONTACT
L
Lili Ma, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here